Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Perindopril Erbumine (also called S9490-3; Pirindopril; ACEON; Perindopril tert-butylamine; Perstarium), the tert-butylamine salt of perindopril, is a long acting and brain penetrant ACE (angiotensin-converting enzyme) inhibitor with anti-hypertensive effects. It inhibits ACE with an IC50 of 1.05 nM and has been approved for use in the treatment of hypertension and heart failure. Perindopril Erbumine can suppress the increase in hippocampal ACE activity and improves cognition in PS2APP-transgenic mice. Perindopril Erbumine displays a higher binding affinity for the bradykinin binding sites than the angiotensin I binding sites of ACE. Perindopril Erbumine inhibits the angiotensin- and Aβ42-to-Aβ40-converting activity of mutated ACE containing two active domains (F-ACE) with IC50 of 0.03-0.1 μM, and 0.01-0.03 μM, respectively.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Eur J Pharmacol.2007 Dec 22;577(1-3):1-6;J Biol Chem.2009 Nov 13;284(46):31914-20.
|
Molecular Formula |
C19H32N2O5.C4H11N
|
|
---|---|---|
Molecular Weight |
441.6
|
|
CAS # |
107133-36-8
|
|
Related CAS # |
Perindopril;82834-16-0
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O=C([C@]([H])(C([H])([H])[H])N([H])[C@]([H])(C(=O)OC([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[H])N1[C@]([H])(C(=O)O[H])C([H])([H])[C@]2([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@]12[H].N([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (226.45 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline: 30 mg/mL  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2645 mL | 11.3225 mL | 22.6449 mL | |
5 mM | 0.4529 mL | 2.2645 mL | 4.5290 mL | |
10 mM | 0.2264 mL | 1.1322 mL | 2.2645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.